A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

OBJECTIVE—Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes. RESEARCH DESIGN AND METHODS—In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting...